Biogen Inc.

NASDAQ:BIIB

Drug Manufacturers - General

Healthcare
$251.41 -1.11%

-$2.21 today

Market cap
$37.16B
Beta
0.18
P/E (TTM)
21.1
EPS (TTM)
$9.32
52W Low $121.05High $205.97

Volume 1.14M

Average 1.17M

BIIB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Biogen Inc.NASDAQ: BIIB

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin narrows to 56.9%

Gross margin was 56.9% in Q2 FY2026, down 7.3 pp from a year earlier. On a trailing-twelve-month basis it was 67.7%, down 4.8 pp year over year. Over 3 fiscal years it narrowed by 7.1 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
56.9%-16.4 pp QoQ
Last fiscal yearDec 2025
70.5%-5.7 pp YoY
LTMJun 2026
67.7%-4.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-7.3 pp——
1 year-5.7 pp——
3 years-7.1 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
70.5%
Year-over-year change
-5.7pp

Gross Margin vs competitors

How BIIB compares with its peers on the latest reported figures

  • BIIB's LTM Jun 2026 gross margin of 67.7% is the lowest of the 11 companies compared; the peer median is 82.8%.
  • Its year-over-year change of -4.8 pp is the 10th highest of 11, against a peer median of -0.7 pp.
  • Over three fiscal years its change of -7.1 pp compares with a peer median of +0.0 pp.
BIIB Competitors Peer median
Gross Margin for BIIB and competitors
Company Period LTM level YoY 3-year change
IONSIonis Pharmaceuticals, Inc.LTM Sep 202698.2% -0.6 pp+0.7 pp
UTHRUnited Therapeutics CorporationLTM Jun 202686.1% -2.8 pp-4.5 pp
VRTXVertex Pharmaceuticals IncorporatedLTM Sep 202685.6% -0.7 pp-2.9 pp
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 202684.9% -0.7 pp-0.6 pp
LLYEli Lilly and CompanyLTM Jun 202683.4% +0.8 pp+6.3 pp
PTCTPTC Therapeutics, Inc.LTM Jun 202682.1% -14.9 pp+2.2 pp
AZNAstraZeneca PLCLTM Sep 202680.1% -2.3 pp+9.8 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202679.7% -3.9 pp-2.0 pp
PFEPfizer Inc.LTM Jun 202673.2% +1.1 pp+8.3 pp
AMGNAmgen Inc.LTM Jun 202672.7% +8.2 pp-4.9 pp
BIIBBiogen Inc.LTM Jun 202667.7% -4.8 pp-7.1 pp
Peer median (excluding BIIB) 82.8%-0.7 pp+0.0 pp

Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.98B10.17B9.84B9.68B9.81B
Cost of Revenue2.11B2.28B2.53B2.31B2.9B
Gross Profit8.87B7.9B7.3B7.37B6.91B
Gross Margin80.8%77.6%74.2%76.1%70.5%
Research & Development3.4B2.6B2.7B2.49B1.95B
Selling, General & Admin2.68B2.41B2.5B2.39B2.43B
Operating Expenses6.08B5.01B5.2B4.88B5.04B
Depreciation & Amortization487.7M518.4M494.8M673.2M779.9M
EBITDA3.92B3.54B2.38B3B2.95B
EBITDA Margin35.7%34.8%24.2%31.0%30.0%
Operating Income2.79B2.89B2.1B2.49B1.88B
Operating Margin25.4%28.4%21.3%25.7%19.1%
Interest Income11M89.3M276.5M67.6M87.8M
Interest Expense253.6M246.6M246.9M250.3M246M
Other Income / Expenses(1.01B)705.3M(800.5M)(584.3M)(476M)
Income Before Tax1.78B3.59B1.3B1.91B1.4B
Pre-Tax Margin16.2%35.3%13.2%19.7%14.3%
Income Tax Expense52.5M632.8M135.3M273.8M108.11M
Net Income1.56B3.05B1.16B1.63B1.29B
Net Margin14.2%29.9%11.8%16.9%13.2%
EPS (Basic)10.4420.978.0211.208.85
EPS (Diluted)10.4020.877.9711.198.83
Weighted Avg Shares149.1M145.3M144.7M145.7M146.7M
Weighted Avg Shares (Diluted)149.6M146M145.6M145.9M146.7M

Biogen Inc.

NASDAQ:BIIB

Intrinsic Alpha fair value

Locked

Current Price

$251.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.